InsiderClue
Stocks · Health care · Pharmaceutical Preparations

PSYENCE BIOMEDICAL LTD.

PBM Clue Score59
Ontario, Canada Fiscal year ends March CIK 0001985062
$4.55 -4.01% Close, 13 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.55 +27.81% Close, 13 Oct 2026

Closing prices at the end of each trading day, from 25 Jan 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2023Net income−3.2EPS, diluted−394.06Fiscal year 2024Net income−51.2EPS, diluted−4,674.25Fiscal year 2025Net income1.0EPS, diluted5.24
FY2023FY2024FY2025
Net income −3.2 −51.2 1.0
Growth
EPS, diluted −394.06 −4,674.25 5.24

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−1.6Fiscal year 2024Operating cash flow−2.9Capital expenditure−0.0Free cash flow−3.0Fiscal year 2025Operating cash flow−3.7Capital expenditure−0.0Free cash flow−3.7
FY2023FY2024FY2025
Operating cash flow −1.6 −2.9 −3.7
Capital expenditure n/a −0.0 −0.0
Free cash flow n/a −3.0 −3.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securities
Fiscal year 2023Cash and securities1.3Shareholders’ equity−0.2Fiscal year 2024Cash and securities0.7Shareholders’ equity−11.0Fiscal year 2025Cash and securities6.1Shareholders’ equity6.7
FY2023FY2024FY2025
Cash and securities 1.3 0.7 6.1
Shareholders’ equity −0.2 −11.0 6.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025† 31 Mar 2025
Revenue and profit
1.6 1.0 0.3
0.4 0.6 1.2
−3.2 −2.8 −3.7
−3.2 −51.2 1.0
Growth
Per share
−394.06 −4,674.25 5.24
−394.06 −4,674.25 5.24
Growth
0.0 0.0 0.2
0.0 0.0 0.2
Growth +30.3%

† The diluted share count jumps at 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 3 years on file.